Senior Correspondent, London
Ben's Feed
Oct 22, 2014

GSK eyes top slot in FTSE 100 index for standalone HIV drugs unit

LONDON, Oct 22 (Reuters) – GlaxoSmithKline, battered
by weak U.S. drug sales and a bribery scandal in China, set out
a bold recovery plan on Wednesday, including an initial public
offering of part of its fast-growing HIV and AIDS drugs
business.

As a standalone company ViiV Healthcare would be among the
top 40 companies in London’s FTSE 100 index, outranking such
household names as retailer Marks and Spencer, GSK Chief
Executive Andrew Witty told reporters.

Oct 22, 2014

Drugmakers to join forces to make millions of Ebola vaccine doses

LONDON (Reuters) – Leading drugmakers plan to work together to accelerate development of an Ebola vaccine and produce millions of doses of the most effective experimental product for use next year.

Johnson & Johnson (JNJ.N: Quote, Profile, Research) said on Wednesday that it aims to produce at least 1 million doses of its two-step vaccine next year and has already discussed collaboration with Britain’s GlaxoSmithKline (GSK.L: Quote, Profile, Research), which is working on a rival vaccine.

Oct 22, 2014
Oct 22, 2014

J&J aims for 1 million Ebola vaccine doses in 2015

LONDON (Reuters) – Johnson & Johnson is accelerating work on its experimental Ebola vaccine and said on Wednesday that it aims to have 1 million doses ready in 2015, of which 250,000 are expected to be available by May.

There is currently no proven vaccine against the deadly disease but several companies are racing to develop products and clinical tests on two – from GlaxoSmithKline and NewLink Genetics – are already under way.

Oct 21, 2014
Oct 21, 2014
Oct 20, 2014
Oct 20, 2014
Oct 17, 2014
Oct 17, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben